Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases

• Status: Active, not recruiting
• Trial end date: 2022-05-31
• Target enrollment: 0
• Participant gender: Male

Summary

This study is a Japanese post-marketing surveillance (PMS) which is required by the regulatory authorities. General objective of PMS is to confirm the clinical usefulness, especially the safety profile of a drug under the routine clinical practice.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Radium Ra 223 dichloride

Criteria

Inclusion Criteria:

• Patients suffered from CRPC with bone metastases

• Patients for whom the decision to initiate treatment with Xofigo is made as per physician's routine clinical practice.

• Xofigo treatment naïve

Exclusion Criteria:

• Patients treated Xofigo previously

• Patients participating in an investigational program with interventions outside of routine clinical practice